WHO Issues Global Health Emergency Over Rapidly Spreading Drug-Resistant Tuberculosis Strain as Cases Detected in U.S. Travelers

The World Health Organization did not issue a global health emergency over a rapidly spreading drug-resistant tuberculosis strain linked to U.S. travelers as of mid-2025, according to WHO and CDC officials. While tuberculosis remains a global health priority, officials confirmed that no new emergency declaration had been made, and responses continue through ongoing strategies rather than a single-event alert.

The World Health Organization continues to classify tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms, as a global health crisis, but it has not issued a new global health emergency declaration specifically tied to drug-resistant tuberculosis (DR-TB) strains linked to U.S. travelers, officials confirmed. WHO’s ongoing response to DR-TB is framed through sustained strategies such as the End TB Strategy and targeted crisis management rather than a single-event emergency alert, according to WHO and Centers for Disease Control and Prevention (CDC) sources.

WHO’s most recent major action on DR-TB was the release of updated consolidated guidelines on April 15, 2025, which introduced new treatment recommendations for MDR and rifampin-resistant TB, including shorter, all-oral regimens designed to improve patient outcomes and reduce treatment duration.

Records from WHO and the CDC show no evidence of a Public Health Emergency of International Concern (PHEIC) or equivalent declaration related to a rapidly spreading DR-TB strain in U.S. travelers as of mid-2025. These guidelines recommend a six-month all-oral regimen known as BDLLfxC (bedaquiline, pretomanid, linezolid, levofloxacin, and clofazimine) for MDR/RR-TB cases and modified nine-month regimens when fluoroquinolone resistance is excluded, WHO officials said.

Historical records indicate that WHO has issued formal disease-outbreak communications concerning DR-TB in relation to air travel, such as a 2007 notice about an XDR-TB patient who traveled on commercial flights between the United States and Europe. That incident prompted passenger contact tracing but did not result in a PHEIC or global emergency declaration. WHO’s guidance on TB and air travel emphasizes that the risk of transmission during flights is relatively low and increases primarily on long-haul flights lasting eight hours or more, particularly for passengers seated close to an infectious individual, according to WHO and CDC documents.

CDC officials noted that most travelers are at low risk of acquiring TB through casual travel, with pre- and post-travel testing recommended mainly for those planning extended stays or work in high-transmission environments such as healthcare facilities, prisons, refugee camps, or homeless shelters. The agency also stated that individuals with active infectious TB, especially drug-resistant forms, should generally avoid commercial air travel until they are non-infectious to prevent potential transmission.

Epidemiological analyses show that while TB cases occur among non-immigrant visitors to the United States—one study documented 14,134 incident TB cases among visitors over multiple years—these cases are managed individually and have not been linked to a newly emergent DR-TB strain associated specifically with U.S. travelers. CDC and WHO sources emphasized that drug-resistant TB remains a significant global health challenge, with hundreds of thousands of MDR/RR-TB cases reported worldwide annually, but the presence of such cases in the U.S. does not constitute a new or rapidly spreading global strain.

Domestically, drug-resistant TB is relatively uncommon compared to the global burden. Highly publicized cases of drug-resistant TB in the United States, including the first documented case of a highly drug-resistant strain in a particular jurisdiction, are managed through case isolation, tailored treatment regimens, and public health follow-up rather than triggering international emergency mechanisms, according to CDC and local health department sources.

WHO’s current activities against DR-TB focus on supporting countries to scale up rapid molecular diagnostics, ensuring access to second-line medications, and strengthening infection prevention and control measures. These efforts reflect a sustained crisis response rather than the activation of a new emergency framework. The agency’s technical and programmatic work, including the 2025 guideline updates, aims to improve treatment outcomes and reduce the burden of DR-TB globally.

Past incidents involving MDR or XDR TB patients traveling internationally by air have led to international collaboration between WHO, CDC, and national health authorities for passenger notification and risk communication. However, these events have been managed as isolated incidents without escalation to a global health emergency. WHO and CDC records do not indicate any recent emergency committee meetings or press releases declaring a new global health emergency related to DR-TB strains detected in U.S. travelers.

Tuberculosis, including drug-resistant forms, continues to be a major public health priority worldwide, requiring ongoing surveillance, diagnosis, and treatment scale-up. WHO and CDC officials stress that the global response to DR-TB involves long-term strategies and technical support rather than single-event emergency declarations. The agencies continue to monitor TB epidemiology closely and update guidelines as new evidence emerges.